Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.4 - $4.27 $33,760 - $360,387
-84,400 Reduced 44.08%
107,050 $42,000
Q2 2022

Aug 15, 2022

SELL
$0.56 - $1.29 $25,200 - $58,050
-45,000 Reduced 19.03%
191,450 $108,000
Q1 2022

May 16, 2022

BUY
$0.72 - $1.86 $20,160 - $52,080
28,000 Added 13.43%
236,450 $265,000
Q4 2021

Feb 14, 2022

SELL
$1.3 - $3.17 $75,400 - $183,860
-58,000 Reduced 21.77%
208,450 $304,000
Q3 2021

Nov 15, 2021

BUY
$2.91 - $4.5 $686,760 - $1.06 Million
236,000 Added 775.04%
266,450 $799,000
Q4 2020

Feb 16, 2021

BUY
$3.42 - $6.36 $104,139 - $193,662
30,450 New
30,450 $160,000

Others Institutions Holding UBX

# of Institutions
1
Shares Held
4.41M
Call Options Held
0
Put Options Held
0

About Unity Biotechnology, Inc.


  • Ticker UBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,036,200
  • Market Cap $14M
  • Description
  • Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...
More about UBX
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.